Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Hypersensitivity Reaction

  Free Subscription


Articles published in Eur Respir J

Retrieve available abstracts of 76 articles:
HTML format



Single Articles


    June 2026
  1. LEIGH MW, Shapiro AJ, Chawla KK, Hazucha MJ, et al
    Tidal breathing nasal nitric oxide measurement as a test for primary ciliary dyskinesia in young children.
    Eur Respir J. 2026;67:2501540.
    PubMed     Abstract available


    April 2026
  2. JIA Y, Ge H, Cai R, Chen X, et al
    Comment on: Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses.
    Eur Respir J. 2026;67:2501724.
    PubMed    


  3. DIAB N, Brister D, Kum E, Wahab M, et al
    Mepolizumab for the treatment of refractory chronic cough in patients with eosinophilic airways disease (MUCOSA): a randomised, double-blind, parallel-group, placebo-controlled trial.
    Eur Respir J. 2026;67:2501573.
    PubMed     Abstract available


    March 2026
  4. GE E, Yu C, Lavigne E, Villeneuve PJ, et al
    Early-life greenness and childhood asthma and allergic rhinitis: An Ontario birth cohort study.
    Eur Respir J. 2026 Mar 12:2502272. doi: 10.1183/13993003.02272-2025.
    PubMed    


  5. ROBERTSON NM, Sharma AK, Yang M, Das SK, et al
    A multi-country cohort study evaluating the prevalence, risk factors, lung function and clinical outcomes of chronic bronchitis in low- and middle-income countries.
    Eur Respir J. 2026;67:2501435.
    PubMed     Abstract available


    February 2026
  6. FAHY JV
    The pathobiology and treatment of mucus plugs in asthma and COPD: state of the art.
    Eur Respir J. 2026 Feb 19:2502358. doi: 10.1183/13993003.02358-2025.
    PubMed     Abstract available


  7. MIEDEMA JR, Bonella F, Buschulte K, Culver DA, et al
    Sarcoidosis: a state-of-the-art review.
    Eur Respir J. 2026;67:2501324.
    PubMed     Abstract available


    December 2025
  8. RYERSON CJ, Adegunsoye A, Piciucchi S, Hariri LP, et al
    Reply: Bronchiolocentric interstitial pneumonia is a morphological term used for lung biopsy and chest imaging pattern and is not a substitute for hypersensitivity pneumonitis.
    Eur Respir J. 2025;66:2502009.
    PubMed    


  9. RAGHU G, Remy-Jardin M, Lynch DA, Myers JL, et al
    Substituting bronchiolocentric interstitial pneumonia for hypersensitivity pneumonitis: a word of caution.
    Eur Respir J. 2025;66:2501604.
    PubMed    


  10. SELMAN M, Buendia Roldan I
    Preserving conceptual clarity: why hypersensitivity pneumonitis should remain a separate entity from bronchiolocentric interstitial pneumonia.
    Eur Respir J. 2025;66:2501793.
    PubMed    


    November 2025
  11. HAKANSSON KEJ, Hansen S, Soendergaard MB, von Bulow A, et al
    Long-term efficacy but rare sustained remission: Individual-level five-year stability in anti-IL5/Ralpha biologic therapy response for severe asthma.
    Eur Respir J. 2025 Nov 27:2500926. doi: 10.1183/13993003.00926-2025.
    PubMed     Abstract available


  12. HANSEN S, von Bulow A, Cooper A, Sandin P, et al
    Mortality in Severe Asthma - results from the NORDSTAR cohort.
    Eur Respir J. 2025 Nov 6:2501289. doi: 10.1183/13993003.01289-2025.
    PubMed     Abstract available


    October 2025
  13. BAUGHMAN RP, Grutters JC, Lower EE, Zhou Y, et al
    Pulmonary sarcoidosis clinical trial end-points: a Delphi study.
    Eur Respir J. 2025;66:2500943.
    PubMed     Abstract available


  14. ANNESI-MAESANO I, Bayram H, Cecchi L, Croft D, et al
    Natural disasters and respiratory health.
    Eur Respir J. 2025;66:2402563.
    PubMed     Abstract available


    August 2025
  15. LEE B, Wong E, Tan T, Rupani H, et al
    Pregnancy, asthma and exacerbations: a population-based cohort.
    Eur Respir J. 2025 Aug 28:2501327. doi: 10.1183/13993003.01327-2025.
    PubMed     Abstract available


    July 2025
  16. LIU KY, Sie JJ, Gao Y, Lo YL, et al
    Functional sequence variants of intergenic long non-coding RNA on Chromosome 17q21 are associated with asthma.
    Eur Respir J. 2025 Jul 3:2500847. doi: 10.1183/13993003.00847-2025.
    PubMed     Abstract available


    June 2025
  17. SHENG-KAI MA K, Brumbaugh B, Saff RR, Phipatanakul W, et al
    Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study.
    Eur Respir J. 2025 Jun 19:2500139. doi: 10.1183/13993003.00139-2025.
    PubMed     Abstract available


  18. HE D, Guler SA, Shannon CP, Ryerson CJ, et al
    Transcriptomics of interstitial lung disease: a systematic review and meta-analysis.
    Eur Respir J. 2025;65:2401070.
    PubMed     Abstract available


    April 2025
  19. AGARWAL R, Sehgal IS, Muthu V, Denning DW, et al
    Reply: Perspectives on high-attenuation mucus, CT and MRI in allergic bronchopulmonary aspergillosis.
    Eur Respir J. 2025;65:2500196.
    PubMed    


  20. DOURNES G, Benlala I, Berger P
    2024 imaging criteria for allergic bronchopulmonary aspergillosis: which diagnostic cut-offs? Are chest radiograph and CT comparable?
    Eur Respir J. 2025;65:2500089.
    PubMed    


    February 2025
  21. CELIS-PRECIADO C, Leclerc S, Duval M, Cliche DO, et al
    Phenotyping the Responses to Systemic Corticosteroids in the Management of Asthma Attacks (PRISMA).
    Eur Respir J. 2025 Feb 13:2402391. doi: 10.1183/13993003.02391-2024.
    PubMed     Abstract available


    January 2025
  22. DEITEREN A, Krupka E, Bontinck L, Imberdis K, et al
    A proof-of-mechanism trial in asthma with lunsekimig, a bispecific nanobody(R) molecule.
    Eur Respir J. 2025 Jan 30:2401461. doi: 10.1183/13993003.01461-2024.
    PubMed     Abstract available


  23. SOENDERGAARD MB, Hjortdahl F, Hansen S, Bjerrum AS, et al
    Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma.
    Eur Respir J. 2025 Jan 9:2401497. doi: 10.1183/13993003.01497-2024.
    PubMed     Abstract available


    December 2024
  24. ARKEMA EV, Sachs MC, Dominicus A, Eklund A, et al
    Inflammatory plasma protein levels are elevated years before sarcoidosis diagnosis: a nested case-control study in Sweden.
    Eur Respir J. 2024;64:2400277.
    PubMed     Abstract available


    November 2024
  25. KHALEVA E, Brightling C, Eiwegger T, Altraja A, et al
    Patient-centred composite scores as tools for assesment of response to biological therapy for paediatric and adult severe asthma.
    Eur Respir J. 2024 Nov 7:2400691. doi: 10.1183/13993003.00691-2024.
    PubMed     Abstract available


  26. JAGGI TK, Agarwal R, Tiew PY, Shah A, et al
    Fungal lung disease.
    Eur Respir J. 2024;64:2400803.
    PubMed     Abstract available


    October 2024
  27. KERMANI NZ, Chung KF, Macis G, Santini G, et al
    Radiomultiomics: quantitative CT clusters of severe asthma associated with multi-omics.
    Eur Respir J. 2024 Oct 10:2400207. doi: 10.1183/13993003.00207-2024.
    PubMed     Abstract available


  28. HAMADA Y, Thomas D, Harvey ES, Stevens S, et al
    Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma.
    Eur Respir J. 2024 Oct 10:2400782. doi: 10.1183/13993003.00782-2024.
    PubMed     Abstract available


  29. MCSORLEY HJ
    RIPK2 inhibition gets the NOD for asthma.
    Eur Respir J. 2024;64:2401372.
    PubMed    


    September 2024
  30. WECHSLER ME, Brusselle G, Virchow JC, Bourdin A, et al
    Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies.
    Eur Respir J. 2024 Sep 26:2400316. doi: 10.1183/13993003.00316-2024.
    PubMed     Abstract available


  31. ZHU Z, Shibata R, Hoffman KL, Cormier J, et al
    Integrated nasopharyngeal airway metagenome and asthma genetic risk endotyping of severe bronchiolitis in infancy and risk of childhood asthma.
    Eur Respir J. 2024 Sep 26:2401130. doi: 10.1183/13993003.01130-2024.
    PubMed     Abstract available


  32. GIBSON PG, McDonald VM
    Integrating hot topics and implementation of treatable traits in asthma.
    Eur Respir J. 2024 Sep 10:2400861. doi: 10.1183/13993003.00861-2024.
    PubMed     Abstract available


  33. LAHOUSSE L
    Overweight and dysanapsis in childhood asthma.
    Eur Respir J. 2024;64:2401164.
    PubMed    


  34. MAKRINIOTI H, Fainardi V, Bonnelykke K, Custovic A, et al
    European Respiratory Society statement on preschool wheezing disorders: updated definitions, knowledge gaps and proposed future research directions.
    Eur Respir J. 2024;64:2400624.
    PubMed     Abstract available


  35. WENZEL SE
    Allergen challenge, eosinophils and the long road to asthma endotypes.
    Eur Respir J. 2024;64:2401316.
    PubMed    


    August 2024
  36. VERSI A, Azim A, Ivan FX, Abdel-Aziz MI, et al
    Host-microbial interactions differ with age of asthma onset.
    Eur Respir J. 2024 Aug 30:2400428. doi: 10.1183/13993003.00428-2024.
    PubMed    


  37. ABDO M, Pedersen F, Kirsten AM, Trinkmann F, et al
    Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD.
    Eur Respir J. 2024 Aug 15:2400347. doi: 10.1183/13993003.00347-2024.
    PubMed    


  38. AILI A, Wang Y, Shang Y, Zhang L, et al
    LPG 18:0 is a general biomarker of asthma and inhibits the differentiation and function of regulatory T cells.
    Eur Respir J. 2024 Aug 15:2301752. doi: 10.1183/13993003.01752-2023.
    PubMed     Abstract available


  39. ALVAREZ-SIMON D, Ait Yahia S, Audousset C, Fanton d'Andon M, et al
    Local Receptor-interacting Protein Kinase 2 inhibition mitigates HDM-induced asthma.
    Eur Respir J. 2024 Aug 8:2302288. doi: 10.1183/13993003.02288-2023.
    PubMed     Abstract available


  40. BLOOM C
    The burden of zoster in asthma: what is left to learn?
    Eur Respir J. 2024;64:2401300.
    PubMed    


  41. KHURANA S, Georas SN
    Stepping down biologics in asthma: is it time to challenge the status quo?
    Eur Respir J. 2024;64:2401168.
    PubMed    


    July 2024
  42. GAUVREAU GM, Sehmi R, FitzGerald JM, Leigh R, et al
    Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled, trial.
    Eur Respir J. 2024 Jul 26:2400512. doi: 10.1183/13993003.00512-2024.
    PubMed     Abstract available


  43. WILKINSON A, Woodcock A
    High-quality and low-carbon asthma care go hand in hand.
    Eur Respir J. 2024;64:2400638.
    PubMed    


  44. SOUMAGNE T, Degano B
    Real world evidence in asthma: what to expect beyond randomised controlled trials?
    Eur Respir J. 2024;64:2400716.
    PubMed    


  45. LU J, Wang Z
    Mendelian randomisation supports no evidence of the association between asthma and coronary heart disease in East Asians.
    Eur Respir J. 2024;64:2400628.
    PubMed    


    June 2024
  46. MORTIMER KJ, Cruz AA, Sepulveda-Pachon IT, Jorga A, et al
    Global herpes zoster burden in adults with asthma: a systematic review and meta-analysis.
    Eur Respir J. 2024 Jun 20:2400462. doi: 10.1183/13993003.00462-2024.
    PubMed     Abstract available


  47. STIKKER B, Trap L, Sedaghati-Khayat B, de Bruijn MJW, et al
    Epigenomic partitioning of a polygenic risk score for asthma reveals distinct genetically driven disease pathways.
    Eur Respir J. 2024 Jun 20:2302059. doi: 10.1183/13993003.02059-2023.
    PubMed     Abstract available


  48. SAIKUMAR JAYALATHA AK, Ketelaar ME, Hesse L, Badi YE, et al
    IL-33 induced gene expression in activated Th2 effector cells is dependent on IL-1RL1 haplotype and asthma status.
    Eur Respir J. 2024 Jun 6:2400005. doi: 10.1183/13993003.00005-2024.
    PubMed    


  49. VERBANCK S, Eddy RL, McIntosh MJ, Parraga G, et al
    Missing airways, ventilation defects and conductive airway physiology in asthma.
    Eur Respir J. 2024 Jun 6:2400242. doi: 10.1183/13993003.00242-2024.
    PubMed    


  50. SOENDERGAARD MB, Bjerrum AS, Rasmussen LM, Lock-Johansson S, et al
    OPTIMAL: Titration of anti-IL5 biologics in severe asthma - An open label randomised controlled trial.
    Eur Respir J. 2024 Jun 6:2400404. doi: 10.1183/13993003.00404-2024.
    PubMed     Abstract available


  51. MCDOWELL PJ, McDowell R, Busby J, Eastwood MC, et al
    Clinical remission with biologic therapies in severe asthma: a matter of definition.
    Eur Respir J. 2024;63:2400160.
    PubMed     Abstract available


  52. BEASLEY R, Noble J, Weatherall M
    The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma.
    Eur Respir J. 2024;63:2400523.
    PubMed     Abstract available


  53. SUOJALEHTO H, Charles-Poucel S, Suuronen K, Ronsmans S, et al
    Presenting clinical data for the hazard classification of chemical respiratory sensitisers.
    Eur Respir J. 2024;63:2400338.
    PubMed    


    May 2024
  54. KJELDGAARD JENSEN S, Tingskov Pedersen CE, Fischer-Rasmussen K, Elsner Melgaard M, et al
    Genetic predisposition to high BMI increases risk of early life respiratory infections and episodes of severe wheeze and asthma.
    Eur Respir J. 2024 May 29:2400169. doi: 10.1183/13993003.00169-2024.
    PubMed     Abstract available


  55. LIU T, Prescott WG, Zhou X
    Advances in Non-Type 2 Asthma in the Severe Cases: from molecular insights to novel treatment strategies.
    Eur Respir J. 2024 May 2:2300826. doi: 10.1183/13993003.00826-2023.
    PubMed     Abstract available


  56. MOSS RB
    T-cells and precision medicine for allergic bronchopulmonary aspergillosis.
    Eur Respir J. 2024;63:2400549.
    PubMed    


  57. RAMAKRISHNAN S, Montgomery B, Pavord ID
    Blood eosinophils and lung function loss: from passive prediction to active prevention?
    Eur Respir J. 2024;63:2400812.
    PubMed    


  58. BUSH A, Randerath W, Roche N
    As needed ICS/formoterol: not all of Europe is equal.
    Eur Respir J. 2024;63:2400408.
    PubMed    


  59. HONG YS, Park HY, Ryu S, Shin SH, et al
    The association of blood eosinophil counts and FEV(1) decline: a cohort study.
    Eur Respir J. 2024;63:2301037.
    PubMed     Abstract available


  60. POLVERINO F, Sin DD
    Type 2 airway inflammation in COPD.
    Eur Respir J. 2024;63:2400150.
    PubMed     Abstract available


    April 2024
  61. HATTER L, Holliday M, Eathorne A, Bruce P, et al
    The carbon footprint of as-needed budesonide-formoterol in mild asthma: a post hoc analysis.
    Eur Respir J. 2024 Apr 12:2301705. doi: 10.1183/13993003.01705-2023.
    PubMed     Abstract available


  62. JACKSON DJ, Pelaia G, Emmanuel B, Tran TN, et al
    Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme.
    Eur Respir J. 2024 Apr 4:2301521. doi: 10.1183/13993003.01521-2023.
    PubMed     Abstract available


  63. KRISHNAN JA, Buhl R
    As-needed ICS/formoterol or as-needed SABA in mild asthma?
    Eur Respir J. 2024;63:2302308.
    PubMed    


  64. PAPI A, Ferreira DS, Tonia T, Schleich F, et al
    Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?
    Eur Respir J. 2024;63:2400395.
    PubMed    



  65. ERJ Podcast April 2024: Allergic bronchopulmonary aspergillosis.
    Eur Respir J. 2024;63:24E6304.
    PubMed    


  66. BLOOM CI
    Reply: Asthma and cardiovascular disease: the strength of triangulation.
    Eur Respir J. 2024;63:2400554.
    PubMed    


  67. TATTERSALL MC, Gangnon RE, Jarjour NN
    Asthma and cardiovascular disease: embracing disease heterogeneity is required.
    Eur Respir J. 2024;63:2400469.
    PubMed    


  68. STANESCU C, Talarico R, Weichenthal S, Villeneuve PJ, et al
    Early life exposure to pollens and increased risks of childhood asthma: a prospective cohort study in Ontario children.
    Eur Respir J. 2024;63:2301568.
    PubMed     Abstract available


  69. VARRICCHI G, Brightling CE, Grainge C, Lambrecht BN, et al
    Airway remodelling in asthma and the epithelium: on the edge of a new era.
    Eur Respir J. 2024;63:2301619.
    PubMed     Abstract available


    March 2024
  70. LUO RG, Wu YF, Lu HW, Weng D, et al
    Th2-skewed peripheral T helper cells drives B cells in allergic bronchopulmonary aspergillosis.
    Eur Respir J. 2024 Mar 21:2400386. doi: 10.1183/13993003.00386-2024.
    PubMed     Abstract available


  71. LIU T, Liu S, Rui X, Cao Y, et al
    Gasdermin B, an asthma-susceptibility gene, promotes MAVS-TBK1 signaling and airway inflammation.
    Eur Respir J. 2024 Mar 21:2301232. doi: 10.1183/13993003.01232-2023.
    PubMed     Abstract available


  72. RUSSELL RJ, Boulet LP, Brightling CE, Pavord ID, et al
    The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.
    Eur Respir J. 2024 Mar 7:2301397. doi: 10.1183/13993003.01397-2023.
    PubMed     Abstract available


    February 2024
  73. AGARWAL R, Singh Sehgal I, Muthu V, Denning DW, et al
    Revised clinical practice guidelines for diagnosing, classifying, and treating allergic bronchopulmonary aspergillosis/mycoses: a Delphi statement from the ISHAM-ABPA working group.
    Eur Respir J. 2024 Feb 29:2400061. doi: 10.1183/13993003.00061-2024.
    PubMed     Abstract available


  74. WANG T, Duan W, Jia X, Huang X, et al
    Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study.
    Eur Respir J. 2024;63:2301720.
    PubMed     Abstract available


    September 2023
  75. PAPI A, Ferreira DS, Agache I, Baraldi E, et al
    European Respiratory Society Short Guidelines for the use of as-needed ICS/formoterol in mild Asthma.
    Eur Respir J. 2023 Sep 7:2300047. doi: 10.1183/13993003.00047-2023.
    PubMed     Abstract available


    August 2023

  76. ERJ Podcast August 2024: Titration of anti-IL-5 biologics in severe asthma.
    Eur Respir J. 2024;64:24E6402.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Hypersensitivity Reaction is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum